Amyotrophic Lateral Sclerosis Essay Research Paper Amyotrophic
Amyotrophic Lateral Sclerosis Essay, Research Paper
Amyotrophic Lateral Sclerosis
Motor Neuron Disease Maladie de Charcot Lou Gehrig’s Disease
What is the Disease?
ALS is an extremely deadly disease affecting the nerve cells that
control the victim’s voluntary muscles. These nerves shrink and eventually die,
leaving the muscles without stimulation. As these muscles go without
stimulation, they too eventually shrink and die. The victim progressively
weakens to the point of complete paralysis of all voluntary muscles and some
involuntary muscles, such as breathing and swallowing, and soon after this point,
death is inevitable.
‘A’ means “Without” ‘Myo’ means “Muscle” ‘Trophic’ means “Nourishment” ‘Lateral’
refers to uneven development of symptoms between right and left sides
‘Sclerosis’ refers to “destruction” of tissue
The History of ALS
A French doctor named Charcot first identified ALS in 1874. It is one
of the most devastating diagnoses a person can receive. ALS is said to start
between the years of 40 and 70, with the exact average being 45.6 years old.
The most classic case of Amyotrophic Lateral Sclerosis is Lou Gehrig. Lou
Gehrig was a New York Yankees first baseman, who from 1923 to 1939, had never
missed a game and had a life time batting average of .340. However, the
symptoms of ALS emerged in 1938, and in 1939, he was diagnosed with the disease.
At that time doctors knew little to nothing about the disease and the only
suggested treatment was the untested vitamin E. So Gehrig ate a daily plate
full of garden grass, until June 2, 1941 when he died at the age of 37.
ALS affects approximately 1 out of every 100,000 people. In the United
States there are around 30,000 Americans affected by ALS, and 3,000 more are
diagnosed with the disease each year, with men being affected slightly more than
women, and in some cases, running in families. However while this is the same
number of new cases as Multiple Sclerosis, Multiple Sclerosis affects around
350,000 Americans. The difference is that 50% of ALS patient’s die within three
years, and 80% die within five. The disease is in some ways quite similar to
Alzheimer’s except with Alzheimer’s you have a body walking around with a
diseased brain, whereas with ALS you have a healthy brain trapped inside a
About one-third of those with ALS become aware of their disease when
their hands become clumsy, causing difficulty performing anything needing fine
finger movements. Another third find a weakness in their legs and may trip
because of a mild foot drop. The remaining one-third notice slurring in their
speech or difficulty swallowing. Because all of these symptoms happen naturally,
it is generally not characterized as ALS until the symptom progressively worsens.
This happens as the affected area’s muscle cells deteriorate, resulting in
muscle tenseness. Frequently one side of the body is affected first and it then
gradually passes to the other side. Muscles in the eyes, anus and bladder are
generally left unaffected.
As there is no known way to prevent this disease, there is also no
specific clinical test to identify ALS. It generally involves a physical
examination, perusing through the patient’s medical history, and neurological
testing. To test muscle activity specialists often use an EMG, or
electromyogram, and will often use CT scans, MRIs, and thorough blood
examination. There is also a recently developed SOD1 scan, the gene now thought
to be the cause for ALS, especially familial ALS. Only 20%, however, of
patients with familial ALS show positive on the SOD1 scan.
Progress of ALS
Until very recently very little was known about ALS, either what started
it or how to treat it. Currently there are 3 types of ALS: classic (sporadic),
familial, and the Mariana Island.
Classic ALS accounts for 90-95% of ALS patients in the U.S. The
infrequent familial form (FALS) is inherited and if your parents had FALS there
is a 50/50 chance you will have it as well. The Mariana Island form is a rare
form of ALS found in patients taken from Guam and Japan. ALS appears evenly
across the globe except in the Mariana Islands in the West Pacific and the Kii
Peninsula of Japan where it is unusually high.
Back during Gehrig’s time little else besides vitamin E was even
considered a “potential” therapy, and there were only guesses as to the cause of
the disease until 1991 when evidence linked FALS to chromosome 21. Then in 1993
the same research team identified a defective SOD1 gene on chromosome 21 as
being responsible. It is now known that structural defects in the Super Oxide
Dismutase, or SOD, enzyme reduces the ability to protect against damage to motor
Traditionally doctors were unable to subscribe anything other than a
good source of Vitamin E, exercise and a healthy mind. However, in June of 1996
the Food and Drug Administration passed the first drug for ALS. The drug
Riluzole was successful in lengthening the life-time of ALS patients, especially
those with FALS. However, there is still no way to dampen the symptoms or
prevent those who don’t have it, from getting it. This still was a big step for
ALS and there are now 21 countries that have approved Riluzole, including the
Czech Republic and all 15 members of the European Union. Gabapentin is also
similar to Riluzole and is being tested for approval by the FDA. More
importantly, a drug known as Myotrophin is being tested as well by the FDA and
may be the first drug to slow the progress of paralysis. Because Myotrophin
acts differently than Riluzole, they, hopefully, can be used in synch as well.
Science News, Vol. 145, page 202 The Sacramento Bee, March 2, 1994, A8 The
Sacramento Bee, June 9, 1996 The Wall Street Journal, June 13, 1995, B7 Applied
Medical Informatics (AMI), 1994 Muscular Dystrophy Association (MDA), January 31,
1996 The New York Times, May 9, 1995 The New York Times, June 13, 1995 Gene
Therapy, March 1995 Mayo Clinic Health Letter, April 1996, page 5 Rhone-Poulenc
Rorer, August 1995 The ALS Association and the Neuromuscular Research Foundation